ViiV Healthcare
Presence
ViiV Healthcare is owned by GSK.
GSK is one of the...
GSK is a company listed under the stock ticker GSK (GB).
GSK has a direct presence in 21 countries.GSK has 29 subsidiaries including GSK ANZ, GSK APAC and GSK Austria.
They are in:
Acquisition, funding and merger involving GSK.
- GSK has announced the acquisition of Sierra Oncology (posted on April 14 2022).
- GSK has announced the acquisition of Affinivax (posted on June 1 2022).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at ViiV Healthcare
- Deborah Waterhouse, Chief Executive Officer
- Regis Simard, Director
- David Redfern, Chairman of the Board
Popular executive movements at GSK
- Tony Wood who is Senior Vice President, Medicinal Science and Technology, will be promoted to Chief Scientific Officer Designate on Aug. 1, 2022 (posted on January 19 2022).
- Hal Barron who is Chief Scientific Officer & President, Research and Development and Director, will become Non-Executive Director on Aug. 1, 2022 (posted on January 19 2022).
- Karenann Terrell, Chief Digital and Technology Officer, has left the company (posted on December 17 2021).
Click here to view some more movements at GSK
Create an alert
to follow the executive moves at ViiV Healthcare.
Pharmaceuticals
GSK has 1,994 competitors including Johnson & Johnson (United States (USA)), Pfizer (United States (USA)) and Roche (Switzerland).
Popular M&A news in Pharmaceuticals
- Catalent Pharma Solutions has acquired Metrics Contract Services (posted on August 12 2022).
- CSL has acquired Vifor Pharma (posted on August 4 2022).
- PharmEasy has just announced a $200 Million fundraising. (posted on July 19 2022).
Popular contacts in Pharmaceuticals
News
Press releases by ViiV Healthcare
- ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil
- ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
- ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices
- ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
- ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
- ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
- ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic
- Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV
- Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
- ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
- View more press releases Close
Social media about ViiV Healthcare
- ViiV Healthcare on Wikipedia, Google News & Yahoo Finance
- ViiV Healthcare on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including David Redfern 
Call ViiV Healthcare at +44 792...
